US Election: Waiting Out a Close Race

US Election: Waiting Out a Close Race

Our Global Head of Fixed Income and Thematic Research, Michael Zezas, outlines how investors should navigate the closing days of the presidential campaign -- including a vote-counting period that could extend past Election Day.


----- Transcript -----


Welcome to Thoughts on the Market. I’m Michael Zezas, Morgan Stanley’s Global Head of Fixed Income and Thematic Research. Today is going to be a little bit different. We’re exactly six days away from the US election. The race is neck-and-neck, and I want to sketch out what investors should expect in the next couple of weeks.

It’s Wednesday, October 30, at 10 AM in New York.

This is an historic election, and the outcome remains highly uncertain. What’s more, there’s a good chance we won’t know the winner on election night due to close vote counts. My colleagues and I have spent a lot of time on this show trying to give our listeners a sense of how the election might impact different economies around the word as well as markets, sectors, and specific industries. But today I want to take a step back and highlight a few things that investors should keep in mind right now.

To sum up what we’ve covered so far: The key policies at stake are taxes, tariffs, and immigration. Congressional composition will be critical in determining the extent of tax cut extensions in either win outcome. Domestic, consumer-oriented sectors are most exposed to tax changes, while clean-tech is the most exposed to potential efforts at a repeal of the Inflation Reduction Act. Macro impacts vary depending on the scope of policies and their sequencing, but we see downside risks to growth in a Republican win outcome.

As our listeners know, a candidate needs 270 Electoral College votes to win. Former President Trump’s most likely path to victory is through the Sun Belt – Arizona, North Carolina and Georgia; while Vice President Harris’ most likely path to victory is through the so-called Blue Wall – Michigan, Wisconsin and Pennsylvania.

In terms of the Senate, polling and prediction markets have consistently implied higher likelihood of Republicans winning control. Democrats are defending more seats in states that Trump won in 2020, as well as more seats in states Biden won by a small margin. As far as the House of Representatives, Republicans need 11 of the 25 toss-up seats to maintain control of the House, and Democrats need 15. The generic ballot is the most reliable House indicator, in our view. It’s a political poll which asks not which candidate you plan to vote for to represent you in Congress, but rather which political party – Democrat, Republican or Independent – that you would support. The generic ballot historically correlates with the House winner, and it currently favors Democrats.

All this leaves us with two key takeaways:

First, don’t expect conclusive results on election night. Early vote data from key states reflects our view that vote-by-mail levels are lower than in 2020 but still elevated versus historical levels. And it may take days to get all the mail-in votes counted.

Second, full election results may differ from early returns. Why is that? A candidate may have a deficit in election night vote counts but still come back to win the race once all ballots are counted. This depends on two key variables: The share of the electorate who vote by mail; and the skew among those ballots toward Democrats – a blue shift – or Republicans – a red shift.

So again, we need to be patient and wait for the final results. And when that happens, we will start digging deep into the post-election outlook for the economy and markets.

Thanks for listening. If you enjoy the show, please leave us a review wherever you listen to podcasts and share Thoughts on the Market with a friend or colleague today.

Episoder(1513)

Andrew Sheets: Four Reasons to Remain Patient

Andrew Sheets: Four Reasons to Remain Patient

Despite a needed correction in recent weeks, a suite of significant risks still hangs over U.S. markets. Chief Cross-Asset Strategist Andrew Sheets explains.

25 Sep 20202min

Michael Zezas: Unlikely Paths to Stimulus May Interest Investors

Michael Zezas: Unlikely Paths to Stimulus May Interest Investors

As hopes for an additional stimulus package wane in the run-up to the U.S. elections, some of the less likely paths to a deal may provide a way out of the current correction. Michael Zezas, Head of U.S. Public Policy Research, explains.

24 Sep 20202min

Mike Wilson: A Correction with Policy Roots

Mike Wilson: A Correction with Policy Roots

Action by Congress and the Fed, and its absence, has paved the way for the recent downturn in equities, putting markets back on a more sustainable footing. Chief Investment Officer Mike Wilson explains.

21 Sep 20203min

Andrew Sheets: The Uncertainty of the Fed’s New Certainty

Andrew Sheets: The Uncertainty of the Fed’s New Certainty

This week, the Fed announced a new framework that could keep interest rates unusually low. So why did markets collectively yawn at the announcement?

18 Sep 20203min

Special Episode: The ABCs of ESG ETFs

Special Episode: The ABCs of ESG ETFs

On this special edition of the podcast, Jessica Alsford, Head of the Global Sustainability Research Team talks with Michael Zezas about the important role ETFs are playing for ESG investing.

16 Sep 20209min

Mike Wilson: Could the Correction Continue Further?

Mike Wilson: Could the Correction Continue Further?

Why gridlock on the next U.S stimulus package—combined with election year uncertainty—suggests there could be more downside in September and October.

14 Sep 20203min

Andrew Sheets: Markets Ponder a Trillion-Dollar Question

Andrew Sheets: Markets Ponder a Trillion-Dollar Question

A downward adjustment in some high-flying U.S. tech stocks has put investors on edge this month, but an impasse on fiscal stimulus negotiations may be the real issue to watch.

11 Sep 20203min

Special Episode: Why Vaccine Discovery is Just the Beginning

Special Episode: Why Vaccine Discovery is Just the Beginning

As COVID-19 vaccine development continues in phase three studies, the logistics of FDA approvals, production and the complex hurdles of distribution are taking shape.

10 Sep 20209min

Populært innen Business og økonomi

stopp-verden
dine-penger-pengeradet
e24-podden
rss-penger-polser-og-politikk
rss-borsmorgen-okonominyhetene
livet-pa-veien-med-jan-erik-larssen
pengepodden-2
rss-vass-knepp-show
finansredaksjonen
utbytte
tid-er-penger-en-podcast-med-peter-warren
okonomiamatorene
morgenkaffen-med-finansavisen
stormkast-med-valebrokk-stordalen
lederpodden
aksjepodden
rss-sunn-okonomi
rss-fri-kontantstrom
rss-andelige-tanker-med-camillo
rss-impressions-2